• Savara presented molgramostim results in autoimmune pulmonary alveolar proteinosis patients with mild diffusion impairment at the CHEST 2026 Annual Meeting.
• The post-hoc analysis of the Phase 2/3 IMPALA trial linked daily treatment to improved pulmonary gas transfer and reduced surfactant buildup.
• Respiratory quality of life also improved over 24 weeks, while lung diffusion capacity was maintained.
• Findings were exploratory, based on eight patients assigned daily molgramostim and three assigned placebo, limiting conclusions about benefits across disease severity.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Savara Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20261021536120) on October 21, 2026, and is solely responsible for the information contained therein.